Replimune Stock Nosedives Again: What’s Driving the September 2025 Sell-Off?
Another brutal day for Replimune shareholders as the biotech's stock tanks—again. Here's why the bears are mauling this once-high-flying name.
Clinical setbacks or just Wall Street capriciousness?
No fresh data to explain the plunge, but the Street's patience wears thinner than a phase trial's placebo group. Remember: biotech rallies get called 'brave,' while sell-offs get called 'rational.'
Cash burn vs. pipeline potential
Analysts start whispering about runway concerns while management keeps waving pipeline posters. Meanwhile, short sellers feast like it's a zero-commission trading day.
The lesson? In biotech, 'disruptive science' often disrupts portfolios first. Stay tuned—this rollercoaster's got more loops coming.
A cloudy future
Well before market open that morning, Anupam Rama from J.P. Morgan changed his recommendation on Replimune from neutral to underweight (sell, in other words). The analyst withdrew his $6 price target and did not set a new one.
Image source: Getty Images.
Rama based much of his new take on the company on the latest developments with its investigational melanoma treatment RP1, according to reports. On Thursday, the company disclosed that it met with Food and Drug Administration (FDA) officials to discuss the regulator's unwillingness to approve the medication. The outcome of those talks, it seemed, was inconclusive.
The analyst wrote that while RP1 clearly performed well in clinical testing, its future is now very much up in the air, with at least accelerated FDA approval not likely to occur.
Another pundit weighs in
Rama was not the only analyst publishing an update on Replimune. His peer Raghuram Selvaraju of H.C. Wainwright authored a note reiterating his neutral recommendation on the stock. It was not immediately clear what price target the prognosticator set for the biotech's stock.
